Compare Novavax Inc (NVAX) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs VanEck Rare Earth/Strategic Metals — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while VanEck Rare Earth/Strategic Metals trades at $60.97 (market cap $1.75B). The key difference: Novavax Inc and VanEck Rare Earth/Strategic Metals are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and VanEck Rare Earth/Strategic Metals for 50 Days on average.
| NVAX | REMX | |
|---|---|---|
Market Cap | $1.82B | $1.75B |
Volume | 6,198,505 | 930,523 |
Sector | Health | Sector/Thematic |
52-Week High | $12.75 | $109.53 |
52-Week Low | $6.22 | $60.58 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $60.58, down 2.1% with a bearish technical outlook. The ETF shows high volatility and faces pressure from rare earth market dynamics. Recent news highlights geopolitical tensions around critical minerals and China's export controls, while institutional interest includes Bank of America increasing its stake by 72.1% in Q2 2026 (SEC filing, August 2026).
Outlook remains cautious due to sector volatility and China dependency risks. Investment appeal lies in strategic positioning for supply chain independence, but high turnover and exposure fluctuations warrant careful risk assessment. Key catalysts include U.S. policy developments and rare earth supply chain expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About VanEck Rare Earth/Strategic Metals
REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.
Read more on REMX →
